Eikon Therapeutics wins FDA clearance for Phase 1/2 trial of prostate cancer candidate EIK1006
What's the deal? Eikon Therapeutics, a clinical-stage drugmaker that uses automated single-molecule microscopy for drug discovery, announced on 17 November 2026 that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EIK1006. The company plans to start the ARGATE-001 Phase 1/2 trial in patients with metastatic prostate cancer that has progressed on established anti-hormone therapy, with dosing expected to begin in 2027 and initial safety and efficacy data in the second half of 2027.
Why it matters: EIK1006 is a next-generation androgen receptor antagonist designed to work against both the normal receptor and the mutated, amplified versions that drive resistance to current prostate cancer therapies such as enzalutamide. It is Eikon's first internally-derived programme to reach human testing, and it targets a real clinical problem: most patients eventually stop responding to existing androgen-directed therapies.
Read more: BioSpace, 17 November 2026